INCYIncyte
$119.69+29% 1Y
$119.69
$90.3052 weeks$129.88
Growth
Is INCY growing?
Incyte's revenue has grown 19% a year over three years, and grown 16% a year over five, with earnings per share compounding at 0.00%.
+19%
Revenue growth, 3-year annual rate · Biotechnology median +21% · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +16%
Revenue growth, 5-year rate · +19% over three · the three-year rate is above the five-year rate
- Earnings per share, 3-year rate
- 0.00%
Earnings per share, 3-year rate · revenue +19% · earnings per share grew slower than revenue
- Years of annual history on file
- 17
Years of annual history on file · FY2009 to FY2025, as filed
Details›
- Revenue FY2021
- $2.99B
- Revenue FY2022
- $3.39B
- Revenue FY2023
- $3.70B
- Revenue FY2024
- $4.24B
- Revenue FY2025
- $5.14B
Annual income statements as filed with the SEC.
Where the revenue comes from
6 quarters, Mar 2025 to Jun 2026JAKAFI, quarter to Jun 2026from $709.4M in Mar 2025$816.7M
JAKAFI$816.7M
OPZELURA$449.7M
JAKAVI Royalty$124.2M
NIKTIMVO$60.3M
MINJUVIMONJUVI$53.7M
7 more segments$152.8M
Biotechnology
The closest names by size in the same industry